On September 12, the first commercialized drug of Sinotau, adenosine Injection(with Chinese trade name 欧达乐®, 20ml:60mg), was supplied to major hospitals nationwide, and formally entered the domestic clinical application. Adenosine injection is the classic drug of choice for drug loading, which was approved by the National Drug Administration (NMPA) for marketing license in January this […]
Beijing, China, the morning of 30 August, 2023-The initiation meeting of the Phase I/II clinical study of [177Lu]Lu-XT033 Injection initiated by Sinotau was successfully held at Beijing Cancer Hospital. This clinical study is to evaluate the safety and tolerability, radiation dosimetry and pharmacokinetic profile, and efficacy of [177Lu]Lu-XT033 Injection in patients with metastatic prostate cancer. […]
Sinotau Pharmaceutical Group, a leading enterprise in targeted radionuclide theranostics, recently announced completion for a new round of financing over RMB1.1 billion. This round of financing was invested by many national organizations, industry groups and well-known investment institutions, including SDIC Venture Capital, Goldstone, China Structural Reform Fund, Genertec Venture Capital, CITIC Securities, etc. China Life Private […]
24-27, June, 2023, the annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) was held in Chicago, USA. The SNMMI annual meeting is currently one of the largest and most influential academic conferences in the field of nuclear medicine and molecular imaging around the world, providing an in-depth understanding of the latest developments […]
On April 26, Jiangsu Sinotau Molecular Imaging Technology Co., Ltd. (“Jiangsu Sinotau”), a Sinotau’s subsidiary company, officially obtained the “Radiation Safety License” by the Department of Ecology and Environment of Jiangsu Province. The successful obtaining of the “Radiation Safety License” indicates that Jiangsu Sinotau has the qualification to use radiological devices, and produce, use and […]
On February 7, Beijing time, Lantheus, a Nasdaq-listed company, acquired Cerveau, a Sinotau’s joint venture, for an upfront payment and potential additional development and commercial milestone payments. This transaction is an important milestone in the development of molecular imaging in Alzheimer’s disease (AD). The main asset of Cerveau is the global rights of MK-6240, […]
Today, the product adenosine injection was approved for marketing by the National Medical Products Administration (NMPA) for myocardial perfusion imaging and echocardiographic drug loading tests to aid in the diagnosis of coronary artery disease. This is the only loading drug with both indications in China, providing a new option for non-invasive examination of myocardial ischemia […]
On December 28, 2022, the clinical trial application for [177Lu]Lu-XT033 injection, a class I new drug developed by Sinotau, was approved, which means [177Lu]Lu-XT033 is one step closer to commercialization and clinical application. The project has already initiated ethical filing and other preparations, and will advance to clinical enrollment as soon as possible. [177Lu]Lu-XT033 injection, which […]
Guangdong Sinotau Molecular Imaging Technology Co., Ltd., a subsidiary of Sinotau, has successfully obtained the “Radiopharmaceutical Production License” A certificate, which means Guangdong Sinotau Molecular Imaging Technology Co., Ltd. has the production site qualification of radiopharmaceuticals. This is also the second qualification certificate of radiopharmaceutical production license obtained by Sinotau, which provides GMP-compliant premises and facilities for the […]
On September 28, Beijing time, Biogen and Eisai, foreign companies dedicated to the R&D of Alzheimer’s disease (AD) drugs, announced that its new AD drug Lecanemab Phase III clinical trial met its primary endpoint, which means that the drug can effectively improve patients’ cognitive ability and slow down the progression of AD. Lecanemab is the first beta-amyloid (Aβ) antibody to achieve positive results in a confirmatory Phase […]
The first subject in the phase III clinical trial of lutetium Lu 177 dotatate, the first targeted therapeutic radiopharmaceutical developed independently by Sinotau, was successfully randomized on September 22, 2022 at the First Medical Center of the Chinese PLA General Hospital which is the group leader unit, and successfully completed dosing on September 24, marking another milestone for this project. About Lutetium Lu 177 Dotatate Lutetium Lu 177 dotatate, the first nuclide therapeutic drug developed […]
On July 8, 2022, Sinotau’s new drug application for florbetaben F18 injection (NeuraceqTM) was accepted by CDE. Neuraceq is a brain β-amyloid (Aβ) positron emission tomography (PET) imaging agent developed by Life Molecular Imaging (LMI) in Germany. It allows for the accurate measurement of β-amyloid (Aβ) levels in the brain of adult patients through PET/CT […]